Sarcopenic obesity is associated with a faster decline in renal function in people with type 2 diabetes

Abstract Aim To evaluate the association between sarcopenic obesity and the decline in estimated GFR in people with type 2 diabetes. Methods We enrolled 745 people with type 2 diabetes (mean age 64.6 years, 53.6% men). Body composition was evaluated using dual‐energy X‑ray absorptiometry. Skeletal muscle index, calculated as appendicular non‐fat mass (kg) divided by height squared (m 2 ), was used to determine sarcopenia. Sarcopenic obesity was defined as the coexistence of sarcopenia and a ratio of android to gynoid fat mass greater than the median values in each gender. The association of sarcopenic obesity both with the annual rate of decline in estimated GFR and a > 30% decline in estimated GFR was evaluated using multivariate linear regression models and Cox proportional hazard models, respectively. Results Participants with sarcopenic obesity were at an increased risk of a high annual rate of decline in estimated GFR , even after adjustment for the confounding variables (standardized β = −0.228, P <0.001). Sarcopenic obesity was also significantly associated with risk of a > 30% decline in estimated GFR (hazard ratio 4.52, 95% CI 2.16–9.47; P < 0.01) in multivariate model. Conclusions Sarcopenic obesity evaluated by dual energy X‑ray absorptiometry is associated with a faster decline in renal function in people with type 2 diabetes.